Samik Pharmaceuticals announces 2026 value-up plan and continued high dividend
- Samik Pharmaceuticals discloses 2026 value-up plan: aims to achieve mid- to long-term vision 'Re-Leap2030'
- Targets 2030 revenue of KRW 130 billion and operating profit of KRW 11 billion, solidifying growth foundation in 2026
- Qualified as high-dividend company: 2025 dividend payout ratio 25%, dividend amount KRW 368 million (up 28.6% YoY)
- Shareholders receiving 2025 year-end dividend eligible for separate taxation benefit when filing 2026 comprehensive income tax
- Key strategies: maximize CSO operational efficiency, strengthen market leadership with innovative drugs, expand CMO orders, advance long-acting injectable platform, diversify via subsidiary Pharmbay
- This plan contains forward-looking information and may change due to future market conditions
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Corporate Value Enhancement Plan (Voluntary Disclosure) (2026 Samik Pharmaceutical Co., Ltd. Corporate Value Enhancement Plan)
- Company: Samik Pharm (014950)
- Submission: Samik Pharm Co., Ltd.
- Receipt: 05-06-2026
- Under KRX KOSDAQ Market Division